Current Research
Study spotlight: J-RISE Project
Eligibility: Identify as Black/African American, over 18 year old, all genders
-
Lead Investigators:
Russell Brewer, DrPH, MPH (University of Chicago)
Maria R Khan, PhD, MPH (New York University)
Sponsor: NIH/NIDA
Introduction:
The purpose of this study is to understand barriers and facilitators to implement STI/HIV prevention among Black sexual minority men (BSMM) and transgender people who have been involved in the criminal justice system, their health care providers and researchers studying these populations.
To improve our understanding of how to best reach and engage BSMM/TGW during re-entry in STI/HIV prevention, this study is a three site (NYC, Chicago, Central NC) qualitative pilot study to identify the community organizations where BSMM/TGW with criminal justice involvement (CJI) can best be reached, the most feasible and acceptable methods of assessing a history of CJI in community care and service organizations to reach the population with STI/HIV prevention, and the most acceptable methods of engaging BSMM/TGW with CJI in care and research. We aim to identify shared and site-specific differences in intervention settings and approaches.
-
Lead Investigators:
Aniruddha Hazra, MD (University of Chicago)
(University of Chicago)
Sponsor: Medical College of Wisconsin (MCW)
Introduction:
Anal cancer is a common cancer among gay, bisexual and other men having sex with men (MSM). Its annual incidence is approximately 50-fold and 5-fold higher among HIV-positive MSM and HIV-negative MSM, respectively, compared to the rest of the general population.
The long-term goal of the Prevent Anal Cancer (PAC) Palpation Study is to decrease morbidity and mortality from anal cancer by increasing detection of anal canal tumors through self- or partner-palpation of the anal canal.
-
Lead Investigators:
John Schneider, MD, MPH (University of Chicago)
Russell Brewer, DrPH, MPH (University of Chicago)
Sponsor: NIH
Introduction:
The “Social network diffusion of COVID-19 prevention for diverse Criminal Legal Involved Communities”, will implement a situation appropriate COVID-19 testing and vaccination social network diffusion intervention – C3 Phase II. C3 Phase II builds upon C3 Phase I, by using a network diffusion approach facilitated through motivational interviewing purposefully geared to mobilize one’s own organic social network to increase situation appropriate testing and vaccine uptake.
-
The goal of this project is to test a social network intervention aimed at improving (or maintaining) engagement in HIV care among adolescent and younger adult Black MSM and transgender patients. The social network intervention includes recruitment of individuals from the social network that serve a supportive function and motivate these individuals to drive adherence to HIV primary care: retention to clinic appointments and adherence to antiretrovirals. This study is a randomized trial funded by the National Institutes of Health. For more information contact Alida Bouris at abouris@uchicago.edu
-
Lead Investigators:
John Schneider, MD, MPH (University of Chicago)
Duncan Dustin, ScD, ScM (Columbia University)
Justin Knox, PhD, MPH, MSc (Columbia University)
Sponsor: Columbia University
Introduction:
“PrEP Uptake and Adherence Among Young Black MSM: Neighborhood and Network Determinants” (N2) is a behavioral study. This study aims to determine the relationship between neighborhood-level factors and pre-exposure prophylaxis (PrEP) uptake and adherence; characterize the relationship between social and sexual network characteristics and PrEP uptake and adherence; and identify interactive effects of neighborhoods and social and sexual networks on PrEP uptake and adherence.
The N2 Cannabis PrEP Study uses innovative methods to rigorously investigate relationships between cannabis use (including polysubstance use), HIV prevention behaviors (e.g., PrEP use/adherence) and biological vulnerability to HIV infection among an existing cohort of Black men who have sex with men (MSM).
The N2 Stimulant Study characterizes stimulant use in the N2 cohort, including use of other drugs (i.e. polysubstance use), and patterns of use over time (e.g., incidence, persistence); identifies network-level and neighborhood-level determinants of stimulant use; and determines how stimulant use impacts HIV transmission through prevention (e.g. PrEP adherence, condom use), treatment (e.g. ART adherence) and amplified biological vulnerability (i.e. rectal inflammation).
-
Lead Investigators:
Moira McNulty, MD, MS (University of Chicago)
John Schneider, MD, MPH (University of Chicago)
Katerina Christopoulos, MD, MPH (UCSF)
Sponsor: NIH/NIMH
Introduction:
Long-acting injectable antiretroviral therapy (LAI-ART) represents the next innovation in HIV therapy. To realize the potential of LAI-ART, the scientific community must anticipate, understand, and address barriers and bottlenecks to implementation. The goal of the LAI-ART study is to identify LAI-ART implementation strategies across patient, provider, and clinic/systems contexts using a mixed-methods, multi-level study structured by the Consolidated Framework for Implementation Research (CFIR) with the goal of creating a care delivery model that optimizes real world use.
